In times of fear and uncertainty in the stock market, investors often shift their focus to safer investment options. This behavior can include moving funds into conservative assets like Treasury bills or leaning toward investments that tend to be less volatile while still offering market exposure, such as blue chip dividend stocks.
Blue chip stocks that pay dividends become particularly appealing during turbulent market conditions for two main reasons. Firstly, their consistent dividend payouts can provide a reliable source of returns, which is especially valuable when the broader market stagnates or declines. Secondly, these stocks are generally known for their long-standing records of dividend growth, often extending decades.
For instance, during the global market upheaval in 2009, a unique investment signal marked potential growth for Nvidia, a once-lesser-known chipmaker. Now, a similar “Total Conviction” signal is emerging for a company that’s a fraction of Nvidia’s size, raising interest among investors once again.
While past performance is not guaranteed to predict future results, historical trends suggest that blue chip dividend stocks typically provide steady gains alongside rising dividend payouts. This dual benefit equips them to thrive in both bullish and bearish market climates.
Among the numerous high-quality dividend stocks, Abbott Laboratories, classified as a Dividend King with over 50 years of consecutive dividend growth, stands out as a notable candidate for those wary of increased market volatility.
Abbott, headquartered in Illinois, operates as a diversified healthcare company, excelling in areas such as medical devices, diagnostics, baby formula, and nutritional supplements. Its robust portfolio has solidified its status as a Dividend King, successfully raising its quarterly cash dividend for 55 consecutive years. Currently, Abbott’s stock boasts a forward yield of approximately 2.8%. While this yield may be moderate compared to others in the market, its long-term potential is significant, given Abbott’s historical average annual payout increase of 9.4% over the past decade.
Despite a recent trend where dividend growth has slowed to about 7%, the company’s payout ratio stands at a sustainable 41.6%, indicating room for future growth. Furthermore, Abbott is currently trading at a competitive valuation compared to its peers in the healthcare sector, with a price-to-earnings ratio of 16.5, while companies like Johnson & Johnson are valued at over 20 times forward earnings.
However, some investors may express concern regarding Abbott’s recent price pullback, questioning its stability amidst a supposedly bullish market. The dip can largely be attributed to its significant acquisition of Exact Sciences, finalized in March for $21 billion. While Abbott has acknowledged that this deal will negatively impact short-term earnings, it has the potential to enhance long-term growth prospects in cancer diagnostics.
In the broader picture, this acquisition may facilitate Abbott’s transition into faster-growing segments of healthcare, potentially divesting more mature segments like its nutritional products. This evolution could lead to improved earnings and dividend growth, alongside stronger overall stock performance.
For investors contemplating whether to buy into Abbott Laboratories now, it’s worth noting that an analyst team from a popular investment advisory service has recently highlighted ten other stocks they believe hold greater promise for substantial returns in the next few years. Historical data shows that earlier recommendations from the same service have yielded impressive returns, underscoring the importance of careful stock selection.
Despite its encouragement for long-term investing, Abbott remains a compelling option for those seeking a steady dividend growth stock, particularly as potential market volatility looms. As the company continues to adapt to market conditions and expand its healthcare focus, its stock may offer strong total returns over time.
